Differential diagnosis between normal endometrium and endometrial hyperplasia with immunostaining cytology using anti-LeY monoclonal antibody

International Journal of Gynecological Cancer

Volumn 13, Issue 1, 2003, Pages 42-46

  Arai, Yuko ^a   Nishida, M ^b  

^a IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b National Hospital Organization Kasumigaura Medical Center   (Japan)

Author keywords

Anti LeY monoclonal antibody; Endometrial hyperplasia; Immunocytochemistry

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LEY; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; PRECANCER; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY;

EID: 0037222345     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13009.x     Document Type: Article

References (22)

1. Jobo T, Takeoka K, Kuramoto H. Study on the long-term follow-up of endometrial hyperplasia. Int J Clin Oncol 1996;1:163-9.
2. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. Cancer 1985;56:403-12.
3. Campbell PE, Barter RA. The significance of atypical endometrial hyperplasia. J Obstet Gynecol Br Com 1961;68:668-72.
4. Gusberg SB, Kaplan AL. Precursors of corpus cancer. Am J Obstet Gynecol 1963;87:662-78.
5. Sherman AI, Brown S. The precursors of endometrial carcinoma. Am J Obstet Gynecol 1979;135:947-56.
6. Sato R, Jobo T, Imai M et al. Cytopathological and clinical findings of endometrial hyperplasia. J Jpn Soc Clin Cytol 1998;37:637-42 (in Japanese).
7. Arai Y, Nishida M, Sato T et al. Study of apoptosis in the normal endometrium and endometrial cancer. J Jpn Soc Gynecol Pathol Colpol 1996;14:75-9 (in Japanese).
8. Hertig AT, Sommers SC. Genesis of endometrial carcinoma. Cancer 1949;2:946-56.
9. Speert H. The premalignant phase of endometrial carcinoma. Cancer 1952;5:927-44.
10. Beutler HK, Dockerty MB, Randall LM. Precancerous lesions of the endometrium. Am J Obstet Gynecol 1963;86:433-43.
11. Gambrell RD, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980;55:732-8.
12. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
13. Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985;56:1452-5.
14. Porrazzi LOC. Cytopathologic criteria of hyperplastic lesions in endometrial sampler. Diag Cytopathol 1988;4:283-7.
15. Abe K, Yamamoto K, Obata K, Hoshiai H, Noda K, Inoue Y. Cytological finding of endometrial hyperplasia. J Jpn Soc Clin Cytol 1998;37:643-9 (in Japanese).
16. Bibbo M, Reale FR, Reale JC et al. Assessment of three sampling technics to detect endometrial cancer and its precursors. Acta Cytol 1979;23:353-9.
17. Minucci D, Torrisi A, Castagnoli B, Lovato N, Febbraro R. Cytological evaluation of endometrial hyperplasia in relation to histological pictures. Eur J Gynaecol Oncol 1984;2:119-25.
18. Meisels A, Jolicoeur C. Criteria for the cytologic assessment of hyperplasia in endometrial samples obtained by the Endopap endometrial sampler. Acta Cytol 1985;29:297-302.
19. Hiraishi K, Suzuki K, Hakomori S, Adachi M. LeY antigen expression is correlated with apoptosis (programmed cell death). Glycobiology 1993;3:381-90.
20. Ma J, Kubushiro K, Tashima Y et al. Expression of human, β 1,4 garactosyltransferase in gynecological cancer cell lines. Int J Oncol 1997;11:117-22.
21. Kubushiro K, Tsukazaki K, Sakuma Y, Sakayori M, Yazawa S, Nozawa S. Enzymatic basis for the accumulation of Lewis b antigen in endometrial cancers. Jpn J Cancer Res 1995;86:361-7.
22. Kubushiro K, Tsukazaki K, Sakuma Y et al. Expression mechanism of human uterine endometrial cancer-specific fucosylated carbohydrate chains: aberrant, α1-4 fucosyltransferase in uterine endometrial cancer-derived cell lines with type I carbohydrate chain. Int J Oncol 1995;6:93-7.